title: Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel.
abstract: Malignant neoplasms of the salivary gland are uncommon entities in which surgical resection of the primary lesion has been accepted as a standard therapeutic option. The efficacy of radiation and systemic chemotherapy has been limited for patients with recurrent, metastatic, or unresectable disease because of unfavorable response rates and the short duration of the response. We treated one patient with recurrent adenoid cystic carcinoma arising from the sublingual gland and one patient with primary adenocarcinoma arising from the parotid gland with transfemoral intraarterial chemotherapy, based on full-dose cisplatin and docetaxel and concurrent external-beam radiotherapy. The doses of cisplatin and docetaxel in the two patients were 80-100 mg/m2 and 10-15 mg/m2, respectively. Docetaxel was infused first, followed by cisplatin. Both patients obtained complete responses. Although complications such as mucositis, anorexia, neutropenia, and ischemic colitis were observed, they were well tolerated and manageable. The concomitant chemoradiotherapy of cisplatin and docetaxel seemed to be a practicable option for patients with recurrent and unresectable salivary gland carcinomas.
authors.affiliation: Department of Otolaryngology, Hirosaki University School of Medicine, 5 Zaifucho, Hirosaki, 036-8562, Japan. maruya@cc.hirosaki-u.ac.jp
authors.forename: Shin-ichiro
authors.initials: S
authors.lastname: Maruya
authors.forename: Atsushi
authors.initials: A
authors.lastname: Namba
authors.forename: Atsushi
authors.initials: A
authors.lastname: Matsubara
authors.forename: Seiji
authors.initials: S
authors.lastname: Kakehata
authors.forename: Ikuko
authors.initials: I
authors.lastname: Takeda
authors.forename: Takashi
authors.initials: T
authors.lastname: Shirasaki
authors.forename: Yoshiomi
authors.initials: Y
authors.lastname: Hatayama
authors.forename: Morio
authors.initials: M
authors.lastname: Nagahata
authors.forename: Junkichi
authors.initials: J
authors.lastname: Yokoyama
authors.forename: Hideichi
authors.initials: H
authors.lastname: Shinkawa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy / Q000532:radiotherapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D010307:Parotid Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy*; D018714:Radiotherapy, Adjuvant; D013362:Sublingual Gland Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy*; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin